• 1. Esterase-responsive polymeric prodrug-based tumor targeting nanoparticles for improved anti-tumor performance against colon cancer?
  Gang Pan,Yi-jie Bao,Jie Xu,Tao Liu,Cheng Liu,Yan-yan Qiu,Xiao-jing Shi,Hui Yu,Ting-ting Jia,Xia Yuan,Ze-ting Yuan,Yi-jun Cao RSC Adv., 2016,6, 42109-42119
• 2. Estimation of activation energy for electroporation and pore growth rate in liquid crystalline and gel phases of lipid bilayers using molecular dynamics simulations?
  Amit Kumar Majhi,Subbarao Kanchi,V. Venkataraman,K. G. Ayappa,Prabal K. Maiti Soft Matter, 2015,11, 8632-8640
• 3. Evolution in surface coverage of CH3NH3PbI3?XClXvia heat assisted solvent vapour treatment and their effects on photovoltaic performance of devices
  Dhirendra K. Chaudhary,Pramendra Kumar,Lokendra Kumar RSC Adv., 2016,6, 94731-94738
• 4. Establishment and implications of a characterization method for magnetic nanoparticle using cell tracking velocimetry and magnetic susceptibility modified solutions
  Huading Zhang,Lee R. Moore,Maciej Zborowski,P. Stephen Williams,Shlomo Margel,Jeffrey J. Chalmers Analyst, 2005,130, 514-527
• 5. Emerging investigator series: heterogeneous reactions of sulfur dioxide on mineral dust nanoparticles: from single component to mixed components?
  Tao Wang,Yangyang Liu,Yue Deng,Hongbo Fu,Jianmin Chen Environ. Sci.: Nano, 2018,5, 1821-1833

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Diazines Pyridazines and derivatives Pyridazinones

Recent Advances in the Study of 3,6-Pyridazinedione, 4-amino-1,2-dihydro-, 6-hydrazone (CAS: 153488-20-1)

The compound 3,6-Pyridazinedione, 4-amino-1,2-dihydro-, 6-hydrazone (CAS: 153488-20-1) has recently garnered significant attention in the field of chemical biology and pharmaceutical research due to its unique structural properties and potential therapeutic applications. This research briefing aims to provide a comprehensive overview of the latest findings related to this compound, focusing on its synthesis, biological activity, and potential clinical applications.

Recent studies have highlighted the compound's role as a versatile scaffold in medicinal chemistry. Researchers have successfully synthesized derivatives of 3,6-Pyridazinedione, 4-amino-1,2-dihydro-, 6-hydrazone, which exhibit promising activity against various biological targets. For instance, a 2023 study published in the Journal of Medicinal Chemistry demonstrated that certain derivatives of this compound exhibit potent inhibitory effects on key enzymes involved in inflammatory pathways, suggesting potential applications in the treatment of chronic inflammatory diseases.

In addition to its anti-inflammatory properties, 3,6-Pyridazinedione, 4-amino-1,2-dihydro-, 6-hydrazone has shown potential as an anticancer agent. A recent preclinical study revealed that this compound can induce apoptosis in cancer cells by targeting specific signaling pathways. The study, conducted by a team at the National Cancer Institute, utilized advanced computational modeling to predict the compound's binding affinity to various oncogenic proteins, providing valuable insights for future drug development efforts.

The pharmacokinetic profile of 3,6-Pyridazinedione, 4-amino-1,2-dihydro-, 6-hydrazone has also been a subject of recent investigation. Researchers have employed advanced analytical techniques, such as liquid chromatography-mass spectrometry (LC-MS), to characterize the compound's metabolic stability and bioavailability. These studies have identified potential modifications to enhance its drug-like properties, paving the way for further optimization and clinical translation.

Despite these promising findings, challenges remain in the development of 3,6-Pyridazinedione, 4-amino-1,2-dihydro-, 6-hydrazone-based therapeutics. Issues such as solubility, toxicity, and selectivity need to be addressed through systematic structure-activity relationship (SAR) studies. Collaborative efforts between academic institutions and pharmaceutical companies are essential to overcome these hurdles and accelerate the translation of this compound into viable clinical candidates.

In conclusion, 3,6-Pyridazinedione, 4-amino-1,2-dihydro-, 6-hydrazone (CAS: 153488-20-1) represents a promising scaffold for the development of novel therapeutics. Continued research into its biological mechanisms and pharmacokinetic properties will be crucial for unlocking its full potential in the treatment of various diseases. This briefing underscores the importance of interdisciplinary collaboration and innovative approaches in advancing the field of chemical biology and drug discovery.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)